

Supplemental Figure 1. Naive allantoic fluid does not cause BMCMC activation. BMCMC were derived by culturing total bone marrow with IL-3 for 5 weeks, supplementing with stem cell factor for the last 2 weeks. $2.5x10^5$ $FcR\varepsilon1^+$ and $CD117^+$ BMCMC were treated with media, naive allantoic fluid, A/WSN/33 (WSN), or a positive control of calcium ionophore (Ca^{2+}) at 40nM or LPS at 5mg/mL. (A) Histamine levels were measured by an EIA 30 minutes after stimulation. (B-C) Cytokine/chemokine (B) and LTB_4 (C) secretion were measured 6 hours after stimulation by either MilliplexTM multiplex analysis or an EIA, respectively. A/WSN/33 was added at an MOI of 1. Data are representative of 2 independent experiments. N.D. = none detected.

Supplemental Table 1. Cytokine and Chemokine Produced by BMCMC after A/WSN/33 treatment.[1]

	A/WSN/33 (pg/ml)[2]
IL-1β	< LOD[3]
IL-5	< LOD
IL-6	742.8 ± 92.8
IL-9	< LOD
IL-15	< LOD
IFNα	< LOD
IFNβ	< LOD
IFNγ	< LOD
TNFα	12.7 ± 3.2
VEGF	< LOD
CCL2 (MCP-1)	89.1 ± 5.8
CCL3 (MIP-1α)	169.6 ± 81.2
CCL4 (MIP-1β)	420.2 ± 36.8
CCL5 (RANTES)	71.3 ± 38.8
CXCL1 (KC)	< LOD
CXCL2 (MIP-2)	17.4 ± 1.4
CXCL9 (MIG)	4.9 ± 2.7
CXCL10 (IP-10)	11.9 ± 2.3

[1]To measure the ability of IAV to induce each cytokine or chemokine, $2.5x10^5$ BMCMC mast cells were treated with A/WSN/33 at an MOI=1 for 6 h. At which time cytokine or chemokine levels in the supernants were measured by Luminex™ multiplex assays.

[2]Uninfected BMCMC had cytokine levels below the detection limit of the assays

[3]LOD = Limit of Detection; IL-1β = 2.0 pg/ml, IL-5 = 0.5 pg/ml, IL-9 = 6.0 pg/ml, IL-15 = 6.5 pg/ml, IFNα = 10.0 pg/ml, IFNβ = 10.0 pg/ml, IFNγ = 0.9 pg/ml, VEGF = 0.3 pg/ml, CXCL1 (KC) = 1.4 pg/ml